Scala Biodesign Launches with $5.5M to Revolutionize Protein Applications
Tel Aviv-based Scala Biodesign has unveiled with $5.5 million in funding led by TLV Partners. The company employs AI, physics-based modeling, and biological data analysis to enhance proteins, generating improved antibodies, enzymes, and vaccine…
Continue Reading